Comparative Pharmacology
Head-to-head clinical analysis: ISORDIL versus NITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISORDIL versus NITROL.
ISORDIL vs NITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing cGMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
None Documented
None Documented
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator